Navigation Links
Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer
Date:2/3/2011

YORK, Pa., Feb. 3, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS; ASX: UNS) today announced that it has appointed Dr. Ramin Mojdeh, formerly Vice President and General Manager of Becton Dickinson (BD) Pharmaceutical Systems, North America, and Worldwide Vice President of Research and Development, BD Medical, as its new Chief Operating Officer and Executive Vice President, effective February 7, 2011.

Dr. Mojdeh comes to Unilife with more than 25 years of business leadership experience across multiple industries, including 18 years in the design, development, manufacturing, sales and marketing of therapeutic and diagnostic medical devices for several multinational companies, including BD, GE Healthcare and Boston Scientific (formerly "Guidant Corporation").  He has developed and maintained strong relationships with many pharmaceutical manufacturers that utilize prefilled syringes for their injectable drugs and vaccines.

As COO, Dr. Mojdeh will lead Unilife's operating team as the Company prepares to enter its next phase of business expansion with the commercial production of the Unifill® ready-to-fill (prefilled) syringe this quarter, and its supply to pharmaceutical customers.  Dr. Mojdeh will also help to expand and accelerate discussions with pharmaceutical companies regarding the Unifill syringe, as well as the commercialization of a number of key pipeline products being developed by the Company.

Dr. Mojdeh spent the last eight years working with BD, one of the world's leading suppliers of medical devices, including prefilled syringes. He served as the Vice President and General Manager of BD Medical, Pharmaceutical Systems, North America from 2008 to 2010. In this role, he directed all aspects of the North America operations including sales, marketing, business development, commercial development, finance, R&D, manufacturing, operations, quality assurance, regulatory affairs, legal affairs and human resources.

During this time, Dr. Mojdeh served as a key board member of the Business Strategy Council that led the worldwide business growth strategy for BD Pharmaceutical Systems, whose annual revenues exceeded $1 billion.  He also led the creation of an innovative new growth business for BD Pharmaceutical Systems in advanced drug delivery.

From 2002 to 2008, Dr. Mojdeh held the position of the Worldwide Vice President of Research and Development for BD Medical, responsible for technology and product innovation and commercialization for the business areas of medical surgical systems, diabetes care, pharmaceutical systems and ophthalmic systems with combined annual revenues of over $4 billion. During this time, he led the process of revamping the product development functions for BD Medical.

He was also a board member of BD Ventures Inc., the venture capital arm of BD, which oversaw all technology and innovation activities across BD.  Furthermore, he has served as the Chairman of the Advanced Drug Delivery Council, aimed at identifying and developing new growth strategies in the drug delivery device space.

Prior to his work with BD, Dr. Mojdeh held the position of Business Director, Invasive Cardiology at GE Healthcare in 2002, and spent ten years with Guidant Corporation, where he held several management positions including Business Director, Advanced Patient Management from 1999 to 2002 and Business Director, Advanced Patient Monitoring System from 1996 to 1999.

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "The addition of Dr. Mojdeh to our executive team and as the leader of our operational divisions is a clear indication of Unilife's commitment to rapid growth and the production of the highest quality medical devices. Our ability to attract executives with the experience and reputation of Dr. Mojdeh is an affirmation of the potential for Unilife's innovative product line. Dr. Mojdeh has extensive experience in driving product innovation, manufacturing advanced medical devices and launching new business ventures.  His detailed knowledge of how prefilled syringes are manufactured and supplied to the highest industry standards should help us secure, expand and consolidate strong commercial relationships with many of the world's largest pharmaceutical and healthcare companies.  

"The appointment of Dr. Mojdeh as COO comes at the right time for Unilife. We are now preparing to commence commercial production of the Unifill syringe, with several key sections of the manufacturing system now either in place or being prepared for delivery to our new facility in York. And the commissioning of our cleanrooms and the requalification of our Unitract® 1mL syringe assembly line are now approaching completion. In addition, Dr. Mojdeh's extensive experience working with pharmaceutical companies will be invaluable as our commercial discussions are now accelerating with a significant number of pharmaceutical companies relating to the Unifill syringe, as well as some of our pipeline products. The appointment of Dr. Mojdeh puts us in a strong position to take Unilife to the next level and attain a true global leadership position in the pharmaceutical market for drug delivery devices."

Dr. Ramin Mojdeh commented, "I am extremely pleased to join the executive team of such a unique and innovative company as Unilife. Unilife is developing an exceptional portfolio of innovative products, with the Unifill syringe in particular representing game-changing technology within the pharmaceutical market for prefilled syringes. With Unilife's new global headquarters complete and commercial production of the Unifill syringe about to commence, the Company is in an extraordinary position to now undertake significant expansion on an international scale. I am excited to have an opportunity to help Unilife expand its commercial relationships and capitalize on its tremendous growth potential."

Dr. Mojdeh received his Ph.D. in Computer Science from the University of Minnesota, Minneapolis Minnesota, and his MBA from Kellogg Graduate School of Management, Northwestern University, Evanston, Illinois.

About Unilife CorporationUnilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator-controlled needle retraction features which are fully integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485-certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):Investor Contacts (Australia)Todd Fromer / Garth Russell

Stuart Fine

Jeff CarterKCSA Strategic Communications

Carpe DM Inc

Unilife CorporationP: + 1 212-682-6300

P: + 1 908 469 1788

P: + 61 2 8346 6500
'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
2. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
3. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
4. Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe
5. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
6. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
7. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
8. Unilife Corporation Announces Financial Results for Fiscal Year 2011 First Quarter
9. Unilife Completes A$23.1 Million Private Placement
10. Unilife Corporation Moves into New State-of-the-Art Manufacturing Facility and Global Headquarters
11. Unilife Receives SPP Applications Exceeding A$12.8 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):